Study reveals why cancer anemia treatment leads to tumor growth
MD Anderson News Release October 15, 2015
EphB4 receptor identified as “trigger” for breast and ovarian tumor stimulation
MD Anderson News Release 10/15/2015
Scientists have shown why a drug widely used to treat chemotherapy-induced anemia in ovarian and breast cancer patients also may shorten survival times in some patients by inadvertently stimulating tumor growth.
Anil Sood, M.D., professor of Gynecologic Oncology and Reproductive Medicine at The University of Texas MD Anderson Cancer Center, led a study that identified the cell receptor EphB4 as a catalyst for a chain of cell-signaling events leading to tumor growth. EphB4 is linked to the cancer anemia therapy known as recombinant human erythropoietin (rhEPO). Erythropoietins (Epos) are protein molecules crucial for red blood cell production.
The study results were published in the Oct. 15 issue of Cancer Cell.
“Epos such as rhEPO has been used to relieve chemotherapy-induced anemia in cancer patients,” said Sood. “Alarmingly, a growing number of studies have demonstrated that this treatment can compromise the overall survival of the patients.”
Based on earlier studies including work done by Molecular Health of Heidelberg, Germany, scientists wondered whether the cell receptor known as EpoR which is normally associated with the anemia drug rhEPO, might be the cause. However, studies showed that EpoR “largely failed” to explain the effects of rhEPO on tumor growth.
“Evidence from other therapeutic areas has also suggested the existence of an alternative Epo receptor,” said Sood. “Such observations, combined with a lack of convincing molecular explanation underlying the effects of rhEpo on cancer growth, prompted us to consider the existence of an alternative Epo receptor.”
Sood’s team revealed EphB4 as a trigger for downstream cell signaling that promotes rhEpo-induced tumor growth and progression. The researchers found that EphB4 enhanced tumor growth via STAT3, a protein or transcription factor vital to gene regulation. The investigation employed both in vivo and in vitro samples.
“The study showed EphB4 as a critical mediator of Epo-induced tumor progression,” said Sood. “Our results have broad implications for understanding Epo biology.”
The discovery of EphB4 as an alternative Epo receptor may open further investigation of how to stop tumor-stimulating effects of Epo-based therapies. While additional validation studies might prove valuable in further defining Epo’s adverse effects, the therapy remains an option for patients with chemotherapy-induced anemia, and patients are informed of possible side effects in advance of treatment.
MD Anderson research team members included Sunila Pradeep, Ph.D., Jie Huang, M.D., Ph.D., Alpa Nick, M.D., Sherry Wu, Ph.D., Kyunghee Noh, Ph.D., Rajesha Rupaimoole, Yunfei Wen, Ph.D., Kshipra Gharpure, Jean Hansen, D.O., Archana Nagaraja, Rebecca Previs, M.D., Hee Dong Han, Ph.D.,Wei Hu, M.D., Ph.D., Lingegowda Mangala, Ph.D., Behrouz Zand, M.D., Masato Nishimura, M.D., Ph.D., Rebecca Stone, M.D., Koji Matsuo, M.D., Guillermo Armaiz-Peña, Ph.D., Heather Dalton, M.D., Christopher Danes, Ph.D., Blake Goodman, Shyon Haghpeykar, Padmavathi Jaladurgam and Robert Coleman, M.D., all of the department of Gynecologic Oncology and Reproductive Medicine; Min Soon Cho, Ph.D., Benign Hematology; Gabriel Lopez-Berestein, M.D., Cristian Rodriguez-Aguayo, Ph.D., Bulent Ozpolat, M.D., Ph.D. and Neslihan Alpay, Ph.D., Experimental Therapeutics; Loren Stagg, Ph.D., Chun Li, Ph.D. and John Ladbury, Ph.D., Biochemistry and Molecular Biology; Jinsong Liu, M.D., Ph.D., Pathology; Diana Urbauer, Biostatistics, and Mien-Chie Hung, Ph.D., Molecular and Cellular Oncology.
Participating institutions included the University of Puerto Rico, San Juan, P.R.; the University of North Carolina, Chapel Hill, N.C.; Molecular Health, GmbH, Heidelberg, Germany; Molecular Neurology, Sygnis AG, Heidelberg, Germany; and China Medical University, Taichung, Taiwan.
The study was funded by Molecular Health, the National Institutes of Health (CA109298, P50CA083639, P50CA098258, CA177909, U54CA151668, UH2TR000943, CA16672, U54CA096300, and T32CA101642), the Ovarian Cancer Research Fund, the Department of Defense (OC120547 and OC093416), the Cancer Prevention and Research Institute of Texas (RP110595 and RP120214), the RGK Foundation, Ms. Lois Chiles and Mr. Richard Gilder, Ms. Judi A. Rees, H.A. and Mary K. Chapman Charitable Foundations, the Blanton-Davis Ovarian Cancer Research Program, the Bettyann Asche Murray Distinguished Professorship, the Meyer and Ida Gordon Foundation #2, The G. Harold and Leila Y. Mathers Charitable Foundation, and the Foundation for Women’s Cancer.